

Joaqu  n Portilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4156409/publications.pdf>

Version: 2024-02-01

142
papers

6,691
citations

81900
39
h-index

69250
77
g-index

180
all docs

180
docs citations

180
times ranked

5700
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. <i>Frontiers in Immunology</i> , 2022, 13, 848630.	4.8	7
2	Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004–2018. <i>BMC Infectious Diseases</i> , 2022, 22, 379.	2.9	5
3	Impact of Advanced HIV Disease on Quality of Life and Mortality in the Era of Combined Antiretroviral Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 716.	2.4	12
4	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	3.0	13
5	Inflammatory biomarkers in the pathogenesis of respiratory dysfunction in people living with HIV. <i>Current HIV Research</i> , 2021, 19, .	0.5	0
6	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	2.2	21
7	Isolation of <i>Candida auris</i> in large hospitals in the Autonomous Community of Valencia; population-based study (2013–2017). <i>Revista Iberoamericana De Micología</i> , 2021, 38, 141-144.	0.9	2
8	Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System. <i>Microorganisms</i> , 2021, 9, 1772.	3.6	2
9	Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2021, 57, 873.	2.0	6
10	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	4.7	42
11	The Role of Mental Health Conditions in the Diagnosis of Neurocognitive Impairment in People Living with HIV. <i>Diagnostics</i> , 2020, 10, 543.	2.6	1
12	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1955-1960.	3.0	4
13	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	3.0	12
14	Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial. <i>Antiviral Therapy</i> , 2019, 24, 425-435.	1.0	19
15	Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 634-641.	1.1	18
16	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.5	9
17	La formación de grado en enfermedades infecciosas, resistencia y uso de antibióticos desde la perspectiva de los estudiantes de Medicina. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 25-30.	0.5	11
18	Malestar emocional de pacientes y familiares en la Unidad de Cuidados Paliativos de un hospital general: un estudio piloto. <i>Medicina Paliativa</i> , 2018, 25, 191-194.	0.0	3

#	ARTICLE	IF	CITATIONS
19	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. <i>Journal of Viral Hepatitis</i> , 2018, 25, 699-706.	2.0	15
20	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	4.7	108
21	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e23-e34.	4.7	83
22	Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 313-318.	2.9	5
23	High Irisin levels in nondiabetic HIV-infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis. <i>Clinical Endocrinology</i> , 2018, 89, 414-423.	2.4	18
24	Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. <i>BMC Cancer</i> , 2018, 18, 112.	2.6	43
25	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. <i>BMC Women's Health</i> , 2018, 18, 24.	2.0	3
26	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	1.0	4
27	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 409.e5-409.e8.	6.0	8
28	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, e36-e44.	2.1	10
29	Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. <i>HIV Medicine</i> , 2017, 18, 482-489.	2.2	1
30	Subclinical atherosclerosis in low Framingham risk HIV patients. <i>European Journal of Clinical Investigation</i> , 2017, 47, 591-599.	3.4	15
31	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017, 4, e536-e546.	4.7	101
32	Simplification to dual therapy (atazanavir/ritonavir+lamivudine) versus standard triple therapy [atazanavir/ritonavir+two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 246-253.	3.0	57
33	Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1127-1133.	1.4	13
34	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. <i>Aids</i> , 2016, 30, 37-44.	2.2	46
35	Biological markers of fertility (inhibin B) in HIV-infected men: influence of HIV infection and antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 436-444.	2.2	5
36	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	3.3	60

#	ARTICLE	IF	CITATIONS
37	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 517-523.	0.5	12
38	Empirical monotherapy with meropenem or combination therapy: the microbiological point of view. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1851-1855.	2.9	5
39	Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir vs efavirenz-based antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 653-661.	2.2	20
40	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
41	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw059.	0.9	34
42	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 516.e1-516.e18.	0.5	11
43	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
44	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1 Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 21-29.	2.1	23
45	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	5.8	26
46	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 515-519.	2.1	190
47	Boosted Lopinavir Versus Boosted Atazanavir Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	5.8	6
48	Dual treatment with atazanavir/ritonavir plus lamivudine versus triple treatment with atazanavir/ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 775-784.	9.1	122
49	Dual treatment with lopinavir/ritonavir plus lamivudine versus triple treatment with lopinavir/ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 785-792.	9.1	131
50	Bone mineral density and inflammatory and bone biomarkers after darunavir/ritonavir combined with either raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , the, 2015, 2, e464-e473.	4.7	69
51	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
52	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). <i>Clinical Microbiology and Infection</i> , 2015, 21, 105.e1-105.e5.	6.0	11
53	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	2.5	19
54	Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19803.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. Journal of the International AIDS Society, 2014, 17, 18945.	3.0	15
56	The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients. Journal of the International AIDS Society, 2014, 17, 19643.	3.0	23
57	Prevalence of <i>Trypanosoma cruzi</i> infection in Latin American pregnant women and level of compliance of the Valencian Health Programme in the city of Alicante. Epidemiology and Infection, 2014, 142, 888-890.	2.1	11
58	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Medicine, 2014, 15, 330-338.	2.2	25
59	Directly observed therapy for chronic hepatitis C: A randomized clinical trial in the prison setting. Gastroenterology Y Hepatología, 2014, 37, 443-451.	0.5	14
60	Measles in adults during an outbreak in Spain: hospitalization associated with gastrointestinal and liver involvement. Infection, 2014, 42, 763-765.	4.7	5
61	Ritonavir-boosted darunavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet, The, 2014, 384, 1942-1951.	13.7	158
62	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enfermedades Infecciosas Y Microbiología Clínica, 2014, 32, 447-458.	0.5	14
63	Consensus document on the management of renal disease in HIV-infected patients. Nefrología, 2014, 34 Suppl 2, 1-81.	0.4	8
64	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. Nefrología, 2014, 34, 768-88.	0.4	1
65	Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. Journal of Antimicrobial Chemotherapy, 2013, 68, 1373-1381.	3.0	11
66	Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet, The, 2013, 381, 735-743.	13.7	455
67	Enfermedades infecciosas en pacientes hospitalizados de más de 89 años de edad. Revista Clínica Española, 2013, 213, 316-318.	0.6	0
68	Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 129-134.	2.1	58
69	What Drives the Number of High-Risk Human Papillomavirus Types in the Anal Canal in HIV-Positive Men Who Have Sex With Men?. Journal of Infectious Diseases, 2013, 207, 1235-1241.	4.0	33
70	Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. Clinical Infectious Diseases, 2013, 56, 143-150.	5.8	62
71	Dolutegravir plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine, 2013, 369, 1807-1818.	27.0	697
72	Anal squamous intraepithelial lesions are frequent among young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV). International Journal of Cancer, 2013, 133, 1164-1172.	5.1	27

#	ARTICLE	IF	CITATIONS
73	Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients. <i>HIV Medicine</i> , 2013, 14, 540-548.	2.2	12
74	Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3512-3520.	3.9	46
75	Inflammation and microbial translocation in treatment-controlled HIV patients. <i>Antiviral Therapy</i> , 2013, 18, 837-840.	1.0	1
76	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study. <i>HIV Clinical Trials</i> , 2013, 14, 204-215.	2.0	3
77	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naïve HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 77-85.	2.1	198
78	Polyostotic Osteitis in Secondary Syphilis in an HIV-Infected Patient. <i>Sexually Transmitted Diseases</i> , 2013, 40, 645-646.	1.7	14
79	Inflammation and microbial translocation in treatment-controlled HIV patients. <i>Antiviral Therapy</i> , 2013, 18, 837-840.	1.0	0
80	Pruritus in HIV-infected patients in the era of combination antiretroviral therapy: a study of its prevalence and causes. <i>International Journal of STD and AIDS</i> , 2012, 23, 255-257.	1.1	21
81	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naïve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. <i>Journal of Clinical Microbiology</i> , 2012, 50, 407-413.	3.9	41
82	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1-Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. <i>HIV Clinical Trials</i> , 2012, 13, 228-232.	2.0	30
83	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012, 26, 2315-2326.	2.2	104
84	Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. <i>Aids</i> , 2012, 26, 2241-2246.	2.2	37
85	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 27-35.	9.1	160
86	Efficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028.	3.0	35
87	Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 2083-2088.	2.9	15
88	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study. <i>Current HIV Research</i> , 2012, 10, 673-678.	0.5	2
89	Clinical Utility of Maraviroc. <i>Clinical Drug Investigation</i> , 2011, 31, 527-542.	2.2	29
90	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). <i>Antiviral Research</i> , 2011, 89, 19-25.	4.1	20

#	ARTICLE	IF	CITATIONS
91	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1346-1350.	3.0	19
92	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.	2.2	26
93	Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naïve patients: A 48-week, multicentre, randomized study (Lake Study). <i>Antiviral Research</i> , 2010, 85, 403-408.	4.1	26
94	The Determination of Total Testosterone and Free Testosterone (RIA) are not Applicable to the Evaluation of Gonadal Function in HIV-Infected Males. <i>Journal of Sexual Medicine</i> , 2010, 7, 2873-2883.	0.6	35
95	Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. <i>Journal of Infection</i> , 2010, 61, 458-464.	3.3	52
96	Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. <i>HIV Medicine</i> , 2010, 11, 545-553.	2.2	15
97	Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. <i>Aids</i> , 2010, 24, 1697-1707.	2.2	174
98	The future of antiretroviral therapy: challenges and needs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 827-835.	3.0	46
99	Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. <i>Aids</i> , 2010, 24, 255-264.	2.2	42
100	Raltegravir Versus Efavirenz Regimens in Treatment-Naïve HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 39-48.	2.1	211
101	Current Prevalence and Characteristics of Dermatoses Associated with Human Immunodeficiency Virus Infection. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 702-709.	0.4	9
102	Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIV-Infected Patients in Spain, 1997-2006. <i>Clinical Infectious Diseases</i> , 2009, 48, 1467-1470.	5.8	52
103	Prevalence of HLA-B*5701 in HIV-Infected Patients in Spain (Results of the EPI Study). <i>HIV Clinical Trials</i> , 2009, 10, 48-51.	2.0	13
104	Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, 147-152.	2.1	110
105	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410.	3.0	6
106	Cutaneous Drug Reactions in HIV-Infected Patients in the HAART Era. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 253-265.	0.4	1
107	The Spanish HIV BioBank: a model of cooperative HIV research. <i>Retrovirology</i> , 2009, 6, 27.	2.0	142
108	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 796-806.	13.7	621

#	ARTICLE	IF	CITATIONS
109	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , 2009, 14, 195-201.	1.0	51
110	Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 178-183.	3.0	15
111	Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study. <i>HIV Clinical Trials</i> , 2008, 9, 375-386.	2.0	3
112	Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. <i>Aids</i> , 2008, 22, F1-F9.	2.2	133
113	Angiolipomas, a rare manifestation of HIV-associated lipodystrophy. <i>Aids</i> , 2008, 22, 552-554.	2.2	9
114	Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 139-147.	2.1	127
115	Update on bacterial infections in immunosuppressed patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 12-18.	0.5	1
116	Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 669-675.	1.9	19
117	Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. <i>Journal of Infection</i> , 2007, 54, 159-166.	3.3	13
118	Ceftazidima en infusión continua en el tratamiento de infecciones por <i>Pseudomonas aeruginosa</i> en una Unidad de Hospitalización a Domicilio. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 71-72.	0.5	0
119	Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 695-701.	2.9	11
120	Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 411-418.	2.9	105
121	Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naïve HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. <i>International Journal of STD and AIDS</i> , 2005, 16, 807-810.	1.1	5
122	Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 33-39.	2.0	23
123	Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 580-1.	2.9	3
124	Predictores de progresión y muerte en pacientes con infección avanzada por el VIH en la era de los tratamientos antirretrovirales de gran actividad. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2004, 22, 142-149.	0.5	1
125	Relapsing Cutaneous Alternariosis in a Kidney Transplant Recipient Cured with Liposomal Amphotericin B. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 51-53.	2.9	21
126	Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniácida. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2003, 21, 293-295.	0.5	5

#	ARTICLE	IF	CITATIONS
127	Drug Toxicity or Syndrome of Immune Restoration Causing Fulminant Cirrhosis After HAART-Induced Immune Recovery. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2002, 21, 153-155.	2.9	8
128	Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors. <i>Aids</i> , 2002, 16, 481-483.	2.2	31
129	Highly active antiretroviral therapy for patients with tuberculosis: the solution or the problem?. <i>Aids</i> , 2002, 16, 1436-1437.	2.2	3
130	Fournier's Gangrene in HIV-Infected Patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001, 20, 910-913.	2.9	7
131	Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. <i>Aids</i> , 2000, 14, 1439-1447.	2.2	45
132	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. <i>Aids</i> , 2000, 14, 727-732.	2.2	53
133	Acalculous Cholecystitis Associated with <i>Plasmodium falciparum</i> Malaria. <i>Clinical Infectious Diseases</i> , 2000, 31, 622-623.	5.8	18
134	Progressive Multifocal Leukoencephalopathy Treated with Cidofovir in HIV-infected Patients Receiving Highly Active Anti-retroviral Therapy. <i>Journal of Infection</i> , 2000, 41, 182-184.	3.3	21
135	Cytomegalovirus Polyradiculopathy Presenting as Bilateral Radial Nerve Palsies in a Patient with AIDS. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 605-606.	2.9	2
136	Usefulness of pp65 Antigenemia for the Early Diagnosis of Cytomegalovirus Disease in Patients with AIDS. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 630-635.	2.9	9
137	A randomized study comparing instruments for measuring health-related quality of life in _HIV-infected patients. <i>Aids</i> , 1999, 13, 1727-1735.	2.2	64
138	Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis?. <i>Journal of Infection</i> , 1998, 37, 84-86.	3.3	2
139	Clinical presentation of HIV infection in patients aged 50 years or older. <i>Journal of Infection</i> , 1998, 37, 213-216.	3.3	9
140	Nosocomial Outbreak of Scabies Clinically Resistant to Lindane. <i>Infection Control and Hospital Epidemiology</i> , 1997, 18, 677-677.	1.8	9
141	Origin of hyperamylasaemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 553-55.	2.2	3
142	Fluconazole plus allopurinol in treatment of visceral leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 37, 1042-1043.	3.0	33